Lee Eun Kyung, Kim Min Joo, Kang Seung Heon, Koo Bon Seok, Kim Kyungsik, Kim Mijin, Kim Bo Hyun, Kim Ji-Hoon, Moon Shinje, Back Kyorim, Song Young Shin, Ahn Jong-Hyuk, Ahn Hwa Young, Won Ho-Ryun, Yoo Won Sang, Lee Min Kyoung, Lee Jeongmin, Lee Ji Ye, Jung Kyong Yeun, Jung Chan Kwon, Cho Yoon Young, Lim Dong-Jun, Kim Sun Wook, Park Young Joo, Na Dong Gyu, Kim Jee Soo
Department of Internal Medicine, Center for Thyroid Cancer, National Cancer Center, Goyang, Korea.
Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea.
Endocrinol Metab (Seoul). 2025 Jun;40(3):307-341. doi: 10.3803/EnM.2025.2461. Epub 2025 Jun 24.
The increasing detection of papillary thyroid microcarcinoma (PTMC) has raised concerns regarding overtreatment. For low-risk PTMC, either immediate surgery or active surveillance (AS) can be considered. To facilitate the implementation of AS, the Korean Thyroid Association convened a multidisciplinary panel and developed the first Korean guideline. AS is recommended for adults with pathologically confirmed Bethesda V-VI PTMC who have no clinical evidence of lymph node or distant metastasis, gross extrathyroidal extension, invasion of the trachea or recurrent laryngeal nerve, or aggressive histology. A baseline assessment requires high-resolution neck ultrasound performed by experienced operators to exclude extrathyroidal extension, tracheal or recurrent laryngeal nerve invasion, and lymph node metastasis; contrast-enhanced neck computed tomography is optional. Patient characteristics, including age, comorbidities, and the capacity for long-term follow-up, should be thoroughly assessed. Shared decision-making should carefully weigh the benefits and risks of surgery versus AS, considering expected oncologic outcomes, potential complications, quality of life, anxiety, medical costs, and patient preference. Follow-up involves neck ultrasound and thyroid function tests every 6 months for 2 years and annually thereafter. Disease progression, defined as significant tumor growth or newly detected nodal or distant metastasis, warrants surgery. Despite remaining uncertainties, this guideline provides a structured framework to ensure oncologic safety and supports patient-centered AS.
甲状腺微小乳头状癌(PTMC)检出率的不断上升引发了对过度治疗的担忧。对于低风险PTMC,可考虑立即手术或主动监测(AS)。为促进AS的实施,韩国甲状腺协会召集了一个多学科小组并制定了首个韩国指南。对于经病理证实为Bethesda V-VI级PTMC且无淋巴结或远处转移、肉眼可见甲状腺外侵犯、气管或喉返神经侵犯或侵袭性组织学临床证据的成年人,推荐采用AS。基线评估需要由经验丰富的操作人员进行高分辨率颈部超声检查,以排除甲状腺外侵犯、气管或喉返神经侵犯以及淋巴结转移;颈部增强计算机断层扫描为可选检查。应全面评估患者特征,包括年龄、合并症以及长期随访能力。共同决策应仔细权衡手术与AS的利弊,考虑预期肿瘤学结果、潜在并发症、生活质量、焦虑程度、医疗费用以及患者偏好。随访包括在2年内每6个月进行一次颈部超声和甲状腺功能检查,此后每年进行一次。疾病进展定义为肿瘤显著生长或新发现的淋巴结或远处转移,此时需要进行手术。尽管仍存在不确定性,但本指南提供了一个结构化框架,以确保肿瘤学安全性并支持以患者为中心的AS。
Endocrinol Metab (Seoul). 2025-6
Cancer Control. 2011-4
JBI Database System Rev Implement Rep. 2016-2
Clin Endocrinol (Oxf). 2023-3
Clin Endocrinol (Oxf). 2025-8
Cancer Res Treat. 2025-4
Eur Arch Otorhinolaryngol. 2025-5
J Pathol Transl Med. 2024-11